Keywords: alkermes, regains, rights, vivitrol, cephalon, along, 120m
Alkermes regains the rights to Vivitrol from Cephalon along with $120M in revenue
Article | 08 December 2008
Alkermes has regained the full US rights to alcoholism treatment Vivitrol (naltrexone) from fellow US drugmaker Cephalon, along with $120.0 million ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
